B Braun Medical Company Profile
✉ Email this page to a colleague
What is the competitive landscape for B BRAUN MEDICAL
B BRAUN MEDICAL has sixteen approved drugs.
There are three US patents protecting B BRAUN MEDICAL drugs.
There are fifty patent family members on B BRAUN MEDICAL drugs in twenty-nine countries and seventy-six supplementary protection certificates in sixteen countries.
Summary for B Braun Medical
| International Patents: | 50 |
| US Patents: | 3 |
| Tradenames: | 16 |
| Ingredients: | 15 |
| NDAs: | 16 |
Drugs and US Patents for B Braun Medical
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B Braun Medical | LIDOCAINE HYDROCHLORIDE | lidocaine hydrochloride | INJECTABLE;INJECTION | 208474-001 | Aug 3, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun Medical | MAGNESIUM SULFATE | magnesium sulfate | INJECTABLE;INJECTION | 207967-002 | Apr 26, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun Medical | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | midazolam | SOLUTION;INTRAVENOUS | 218454-001 | May 1, 2025 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| B Braun Medical | CLOROTEKAL | chloroprocaine hydrochloride | SOLUTION;INTRATHECAL | 208791-001 | Sep 26, 2017 | DISCN | Yes | No | 8,969,412 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| B Braun Medical | TROMETHAMINE | tromethamine | SOLUTION;INJECTION | 211558-001 | Dec 9, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun Medical | PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | piperacillin sodium; tazobactam sodium | POWDER;INTRAVENOUS | 206056-002 | Apr 3, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for B Braun Medical Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1931304 | ⤷ Start Trial |
| Slovenia | 1931304 | ⤷ Start Trial |
| Canada | 2878714 | ⤷ Start Trial |
| Serbia | 53077 | ⤷ Start Trial |
| Portugal | 2900216 | ⤷ Start Trial |
| Mexico | 2015007288 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for B Braun Medical Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0247633 | 62/1997 | Austria | ⤷ Start Trial | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
| 1411900 | 2011C/016 | Belgium | ⤷ Start Trial | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
| 1499331 | 122014000007 | Germany | ⤷ Start Trial | PRODUCT NAME: NATRIUMSULFAT, MAGNESIUMSULFAT UND KALIUMSULFAT; NAT. REGISTRATION NO/DATE: 86203.00.00 20130808; FIRST REGISTRATION: BELGIEN BE434323 20130220 |
| 2957286 | LUC00094 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 0162036 | C300028 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929 |
| 2957286 | CA 2018 00043 | Denmark | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
